Bone morphogenetic protein signalling is required for the anti‐mitogenic effect of the proteasome inhibitor MG‐132 on colon cancer cells

William Ka Kei Wu(Quantitative BioSciences)
British Journal of Pharmacology
April 14, 2008
Cited by 33


Related Papers